Figure 1

OX40 and OX40L expression on hematopoietic cells. OX40 expression was analyzed on hematopoietic cells by flow cytometry. (a) Gating strategy for two exemplary AML samples is outlined: viable (7-AAD⁻), singlets, mononuclear cells, blast marker (AML1: CD34⁺/CD117⁺. AML2: CD33⁺) and OX40 or OX40L expression as percentage. The histogram shows the representative OX40/OX40L staining (filled peaks) and the corresponding isotype control (open peaks). (b) OX40 expression on blasts of AML patients are depicted as SFI levels (analyzed patients n = 70, positive patients n = 41) and percentage of OX40 positive blasts (analyzed patients n = 70, positive patients n = 30) (boxplots with min/max whiskers). SFI levels and percentage of positive cells above 1.5 and 10%, respectively, were considered as positive expression (dotted line). (c) OX40L expression on blasts of AML patients are depicted as SFI levels (analyzed patients n = 86, positive patients n = 37) and percentage of OX40 positive blasts (analyzed patients n = 86, positive patients n = 30) (boxplots with min/ max whiskers). (d, e) Correlation between the expression of OX40⁺ and OX40L⁺ cells as percentage (d) and SFI (e) (p value and spearmans ρ).